Dr Reddy's inks pact with Gilead to manufacture COVID-19 drug

As per the non-exclusive licensing agreement, Gilead will grant the Hyderabad-based drug maker the right to register and manufacture its investigational drug Remdesivir in 127 countries, Dr Reddy's Laboratories said in a statement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2UEEq7u
via IFTTT